You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
The firm's whole-genome amplification chemistry may help researchers better understand cancer heterogeneity, even between cells.
The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.
An analysis of B cell adaptive immune receptor sequences in 10 individuals uncovered exceptionally diverse antibody repertoires with a subset of shared antibody clonotypes.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.